by jtcir-auto | Jan 10, 2023 | Press Releases
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing...
by jtcir-auto | Nov 3, 2022 | Press Releases
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS)...
by jtcir-auto | Nov 3, 2022 | Press Releases
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS)...
by jtcir-auto | Aug 29, 2022 | Press Releases
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal Phase 3 study “DETECT-trial” of macimorelin for the...
by jtcir-auto | Aug 29, 2022 | Press Releases
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal Phase 3 study “DETECT-trial” of macimorelin for the...